Prevalence of Frailty and Its Predictors Among Patients With Cancer at the Chemotherapy Stage: Systematic Review
Prävalenz von Frailty und Prädiktoren bei Patient:innen mit Krebs in der Chemotherapiephase: systematische Übersichtsarbeit
JMIR Cancer · 24.07.2025 · 11 · e69936-e69936
DOI: 10.2196/69936 ↗Auf einen Blick
Die Übersichtsarbeit fand bei Patient:innen mit Krebs unter Chemotherapie eine Frailty-Prävalenz von 35 %. Mehrere Faktoren waren mit Frailty assoziiert.
Fragestellung
Welche Risikofaktoren treiben die Frailty-Progression während der Chemotherapie bei Patient:innen mit Krebs?
Methode
Systematische Übersicht observationaler Studien; Suche in PubMed, Web of Science, Embase, CNKI, VIP und SinoMed bis Februar 2025, aktualisiert im Mai 2025.
Ergebnisse
14 Studien mit 3879 Patient:innen und 23 Faktoren. Frailty-Prävalenz 35 % (95 %-KI 22 %–50 %). Assoziiert waren u. a. Krebsstadium, Chemotherapiehäufigkeit, Transfer, Hämoglobin, Leukozyten, Komorbidität und Hypoproteinämie.
Einschränkungen
Heterogenität der Bewertungsinstrumente und Populationsbias schränkten die Generalisierbarkeit ein.
Schlussfolgerung der Autor:innen
Frailty während der Chemotherapie war stark mit fortgeschrittenem Stadium, häufigeren Zyklen, Metastasen, Anämie, Leukopenie, Komorbiditäten und Hypoproteinämie verbunden.
Kernaussagen
- Frailty-Prävalenz während der Chemotherapie: 35 %
- Mehrere klinische Faktoren waren mit Frailty assoziiert
- Frailty-Screening in den Chemotherapieablauf integrieren
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Systematische Übersicht in der Zeitschrift JMIR Cancer, online erschienen am 24.07.2025. Verfasst von Tingting Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Nursing Department, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shang…. Hauptthemen laut MEDLINE: Neoplasms, Frailty, Antineoplastic Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Chemotherapy causes physiological, psychological, and social impairments in patients with cancer. Frailty reduces the effectiveness of chemotherapy and increases the toxicity associated with radiotherapy and chemotherapy, the possibility of chemotherapy failure, and adverse outcomes. However, factors affecting chemotherapy-related frailty in patients with cancer remain unclarified.
Objective
This systematic review aimed to identify risk factors driving frailty progression during chemotherapy in patients with cancer.
Methods
A comprehensive systematic search was conducted on PubMed, Web of Science, Embase, China National Knowledge Infrastructure, China Science and Technology Journal Database (VIP), and SinoMed for observational studies (cohort, cross-sectional, or case-control) on factors affecting the debility-of-chemotherapy stage in patients with cancers between the inception of the database and February 2025, with an updated search executed in May 2025. Literature screening, quality evaluation using the Newcastle-Ottawa Scale and Agency for Healthcare Research and Quality checklist, and data extraction were conducted independently by 2 authors. Meta-analysis, effect size combination, sensitivity analysis, and publication bias analysis were performed using RevMan (version 5.4; The Cochrane Collaboration) and R (version 4.4.3; R Foundation).
Results
The analysis comprised 14 studies (8 cross-sectional, 2 repeated cross-sectional, 3 cohort, and 1 mixed-design), including 3879 patients with cancer and 23 influencing factors. Methodological quality assessment using Agency for Healthcare Research and Quality (mean 8.8, SD 1.3, 95% CI 7.9‐9.7; SE 0.4) and Newcastle-Ottawa Scale (mean 8.0, SD 1.0, 95% CI 6.7‐9.3; SE 0.6) revealed 73% (8/11) of cross-sectional studies as high-quality. The meta-analysis showed a 35% (95% CI 22%‐50%) prevalence of frailty during chemotherapy in these patients. Cancer stage (odds ratio 1.99, 95% CI 1.64‐2.42), chemotherapy frequency (odds ratio 2.60, 95% CI 1.83‐3.70), transfer (odds ratio 2.18, 95% CI 1.50‐3.17), hemoglobin (odds ratio 0.29, 95% CI 0.18‐0.47), white blood cell (odds ratio 0.37, 95% CI 0.21‐0.65), comorbidity (odds ratio 1.93, 95% CI 1.30‐2.86), and hypoproteinemia (odds ratio 1.74, 95% CI 1.31‐2.30) were risk factors for frailty in patients at the chemotherapy stage.
Conclusions
Frailty during chemotherapy was strongly associated with advanced cancer stage, frequent treatment cycles, metastasis, anemia, leukopenia, comorbidities, and hypoproteinemia. Clinically actionable findings emphasized hemoglobin and albumin monitoring as preventive targets, while heterogeneity in assessment tools and population bias limited generalizability. The integration of frailty screening into chemotherapy workflows is urgent to mitigate treatment-related functional decline.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nursing Department, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, 2699 West Gaoke Road, Pudong…
- School of Medicine, Tongji University, Shanghai, China.
- Emergency Department, Shanghai Tenth People's Hospital, Shanghai, China.
- School of Nursing and Health Studies, Hong Kong Metropolitan University, Hong Kong, China.
ORCID-Profile: Tingting Wang, Jinxia Jiang, Zihe Song, Xianliang Liu, Minhui Zhong, Chan Yu, Runa Zhang, Xia Duan
Zitieren
APA
Wang, T., Jiang, J., Song, Z., Liu, X., Zhong, M., Yu, C., Zhang, R., & Duan, X. (2025). Prevalence of Frailty and Its Predictors Among Patients With Cancer at the Chemotherapy Stage: Systematic Review. JMIR Cancer, 11, e69936-e69936. https://doi.org/10.2196/69936
Vancouver
Wang T, Jiang J, Song Z, Liu X, Zhong M, Yu C, et al. Prevalence of Frailty and Its Predictors Among Patients With Cancer at the Chemotherapy Stage: Systematic Review. JMIR Cancer. 2025;11:e69936-e69936. doi:10.2196/69936
BibTeX
@article{Wang2025,
author = {Wang, Tingting and Jiang, Jinxia and Song, Zihe and Liu, Xianliang and Zhong, Minhui and Yu, Chan and Zhang, Runa and Duan, Xia},
title = {Prevalence of Frailty and Its Predictors Among Patients With Cancer at the Chemotherapy Stage: Systematic Review},
journal = {JMIR Cancer},
year = {2025},
volume = {11},
pages = {e69936--e69936},
doi = {10.2196/69936}
}
EUVIMED